Category Archives: Dangerous Drugs

FDA Reports Excess Radiation from PET scan

The U.S. Food and Drug Administration (FDA) is now alerting healthcare professionals to stop using CardioGen-82 (manufactured by Bracco Diagnostics, Inc.) for cardiac positron emission tomography (PET) scans. The FDA reports that patients undergoing a CardioGen-82 PET scan are being exposed to excess radiation. A PET scan is a unique type of imaging test that -->

Tylenol Use Linked to Blood Cancer

In a study published this week by the Journal of Clinical Oncology, researchers  linked acetaminophen to several forms of blood cancers.  Acetaminophen is the main ingredient in over-the-counter products like Tylenol and Excedrin, and it is also found in many cold medicines. The association of cancer with acetaminophen use was greater among women than among -->

Combining Painkillers with Tylenol: FDA Warns of Acetaminophen and Liver Injuries

Kenneth Fromson is a Partner at Finkelstein & Partners, LLP, and participates in the firm’s pharmaceutical litigation. Last week, the FDA announced a new labeling requirement for drug companies who sell prescription pain medications that include acetaminophen.  Specifically, because of a risk of serious liver injury  — or death — consumers will get the benefit -->

Following $36 Million Verdict, Philadelphia Judge Paves Way for Finkelstein’s Next Prempro Trial

Mr. Fromson is a Partner with Finkelstein & Partners, LLP, and participates in the firm’s litigation regarding dangerous drugs. Last week, Judge Sandra Moss rejected a request to dismiss the lawsuits of 4 women who claim they suffered breast cancer from drugmaker Wyeth’s hormone therapy drug, Prempro. Wyeth, based in Madison, NJ, was acquired by -->

U.S. Supreme Court to Decide Whether Victims Can Sue Generic Drugmakers For Inadequate Labeling

Mr. Fromson is a Partner with Finkelstein & Partners, LLP, and participates in the firm’s litigation regarding pharmaceuticals. Drug companies who manufacture and sell generic drugs reap the profits from selling the bioequivalent versions of their counterpart brand name drugs; but they want to avoid responsibility when a victim of their generic drug seeks compensation -->